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Endovascular-assisted versus conventional
in situ saphenous vein bypass grafting:
Cumulative patency, limb salvage, and cost
results in a 39-month multicenter study
David Rosenthal, MD, Elias J. Arous, MD, Steven G. Friedman, MD, Michael
D. Ingegno, MD, Brad L. Johnson, MD, Larry W. Kraiss, MD, John D.
Martin, MD, Mark W. Moritz, MD, Giancarlo Piano, MD, Edward E.
Rigdon, MD, Stephen B. Self, MD, and L. Laszlo Pallos, PhD, Atlanta, Ga;
Worcester, Mass; Manhasset, NY; Miami and Tampa, Fla; Salt Lake City, Utah;
Annapolis, Md; Morristown, NJ; Chicago, Ill; Jackson, Miss; and Louisville, Ky
Objective: In this retrospective multicenter study, the results of a minimally invasive
method of endovascular-assisted in situ bypass grafting (EISB) versus “open” conven-
tional in situ bypass grafting (CISB) were evaluated with a comparison of primary and
secondary patency, limb salvage, and cost.
Methods: Enrolled in this study were 273 patients: 117 underwent CISB (42
femoropopliteal, 75 femorocrural) and 156 underwent EISB (41 femoropopliteal, 115
femorocrural). EISB was performed with an angioscopic Side Branch Occlusion system
and an angioscopically guided valvulotome. All the patients underwent follow-up exam-
ination with serial color-flow ultrasound scanning.
Results: Both groups had similar comorbid risk factors for diabetes mellitus, coronary
artery heart disease, hypertension, and cigarette smoking. The primary patency rates
(CISB, 78.2% ± 5% [SE]; EISB, 70.5% ± 5%; P = .156), the secondary patency rates
(CISB, 84.1% ± 4%; EISB, 82.9% ± 5%; P = .26), and the limb salvage rates (CISB,
85.8%; EISB, 88.4%; P = .127) were statistically similar, with a follow-up period that
extended to 39 months (mean, 16.6 months; range, 1 to 40 months). In veins that were
less than 2.5 to 3.0 mm in diameter, the EISB grafts fared poorly, with an increased inci-
dence of early (12-month) graft thromboses (CISB, 10 grafts, 8.5%; EISB, 24 grafts,
15.3%). However, wound complications (CISB, 23%; EISB, 4%; P = .003), mean hospi-
tal length of stay (CISB, 6.5 days ± 4.83; EISB, 3.2 days ± 3.19; P = .001), and mean
hospital charges (CISB, $25,349 ± $19,476; EISB, $18,096 ± $14,573; P = .001) were
all significantly reduced in the EISB group.
Conclusion: The CISB and EISB midterm primary and secondary patency and limb sal-
vage rates were statistically similar. In smaller veins (< 2.5 to 3.0 mm in diameter), how-
ever, EISB is not appropriate because overly aggressive instrumentation may cause inti-
mal trauma, with resultant early graft failure. With the avoidance of a long leg incision in
the EISB group, wound complications and hospital length of stay were significantly
reduced, which lowered hospital charges and justified the additional cost of the endovas-
cular instruments. When in situ bypass grafting is contemplated, EISB in appropriate
patients is a safe, minimally invasive, and cost-effective alternative to CISB. (J Vasc Surg
2000;31:60-8.)
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In the past decade, surgeons have witnessed a
remarkable evolution in the treatment of arterial dis-
ease. With patients who require treatment for
infrainguinal arterial occlusive disease, the in situ
saphenous vein is the conduit many surgeons prefer.
In an attempt to make the in situ saphenous vein
bypass grafting operation less invasive, an endovascular
method of valvulotomy and side branch occlusion with
angioscopic surveillance was developed. The purpose
of this retrospective multicenter study was the evalua-
tion of the results of this minimally invasive endovas-
cular-assisted in situ bypass grafting procedure (EISB)
versus the “open” or conventional in situ bypass graft-
ing procedure (CISB) with the comparison of primary
and secondary patency, limb salvage, and cost.
METHODS
Between May 1992 and February 1999, 273
patients underwent in situ saphenous vein bypass
grafting in a concurrent, retrospective multicenter
study. One hundred seventeen patients underwent
CISB (42 femoropopliteal and 75 femorocrural), and
156 patients underwent EISB (41 femoropopliteal
and 115 femorocrural). All the patients underwent
operation by the same surgeons from each center dur-
ing the study period. Between May 1992 and January
1995, 71 CISBs were performed with Institutional
Review Board approval. Commencing in February
1995, EISB procedures were performed by three sur-
geons (D.R., G.P., J.D.M.) as part of a Food and
Drug Administration clinical trial group. In July
1997, the Side Branch Occlusion system (Baxter
Healthcare, Irvine, Calif) and the Fogarty irrigating
valvulotome (Baxter Healthcare) received Food and
Drug Administration approval, and, as surgeons were
trained in the EISB technique, these patients entered
the study. The study centers and the number of EISBs
consisted of: Georgia Baptist Medical Center, Atlanta,
Ga (n = 27); St Vincents-Memorial Hospital,
Worcester, Mass (n = 19); North Shore University
Hospital, Manhasset, NY (n = 9); Baptist Hospital,
Miami, Fla (n = 12); University of South Florida,
Tampa, Fla (n = 5); University of Utah, Salt Lake
City, Utah (n = 10); Anne Arundel Medical Center,
Annapolis, Md (n = 16); Morristown Memorial
Hospital, Morristown, NJ (n = 18); University of
Chicago, Chicago, Ill (n = 21); University of
Mississippi, Jackson, Miss (n = 11); and Jewish
Hospital, Louisville, Ky (n = 8). The indications for
operation included rest pain in 119 cases (70 CISB,
49 EISB), non-healing ulcers in 84 cases (35 CISB,
49 EISB), gangrene in 54 cases (29 CISB, 25 EISB),
disabling claudication in 11 cases (6 CISB, 5 EISB),
and popliteal aneurysm in five cases (4 CISB, 1
EISB). Of the patients, 153 were men, and the mean
age of all the patients was 66.4 years (range, 37 to 87
years). One hundred thirty-two patients (49%) had a
cigarette smoking history, 139 (52%) had hyperten-
sion, 131 (48%) had diabetes mellitus, 104 (38%) had
coronary artery disease, and 15 (5%) had renal failure
(serum creatine, >2 mg/mL; Table I).
During EISB, standard incisions were made over
the proximal femoral artery/vein and the saphenous
vein at the location of the distal anastomosis. The
saphenous vein was mobilized only for enough length
to permit each anastomosis. Whenever possible, easily
identified side branches were ligated. After systemic
heparin administration and division of the saphenous
vein from the common femoral vein, the most proxi-
mal valve in the vein was excised.1 The Side Branch
Occlusion system then was inserted directly into 
the proximal saphenous vein, and the Fogarty irrigat-
ing valvulotome was introduced into the distal saphe-
nous vein and passed proximally. The Side Branch
Occlusion system and the valvulotome then were
advanced in tandem down the saphenous vein, and
valvulotomy and endovascular side branch occlusion
were performed with direct angioscopic surveillance.
Irrigation was kept to a minimum, but, if more than
1500 mL of irrigation were used, the patient was
given a diuretic (ie, furosemide, 20 mg/ms). Only
side branches larger than 1 mm and smaller than 5
mm in diameter were occluded with 2-mm, 3-mm, or
4-mm Gianturco coils (Cook, Inc, Indianapolis, Ind).
Side branches larger than 5 mm diameter were surgi-
cally ligated via a small incision. After side branch
occlusion and valvulotomy, the proximal and distal
anastomoses were performed in a standard fashion.
Completion arteriography was used to confirm occlu-
sion of venous side branches and patency of the
bypass graft. Any residual arteriovenous fistulae (AVF)
or missed AVF were ligated.
Table I. Risk factors
CISB (n = 117) EISB (n = 156)
Mean age (years) 66 67
Male gender 64 (55%) 89 (57%)
Smoking history 59 (50%) 73 (48%)
Hypertension 63 (54%) 76 (48%)
Diabetes mellitus 51 (44%) 80 (51%)
Coronary artery heart disease 45 (38%) 59 (38%)
Renal failure 9 (8%) 6 (4%)
CISB, Conventional in situ bypass grafting; EISB, endovascular-
assisted in situ bypass grafting.
The “open” CISB procedures were performed
by the same surgeons between 1992 and the end of
the study. The operative choice was made on the
basis of the surgeons’ preference or whether there
was a contraindication to EISB determined as the
study evolved (eg, renal failure with volume restric-
tion, a saphenous vein < 3 mm in diameter). The
CISB was performed with exposure of the saphe-
nous vein from the proximal to the distal anasto-
moses. The proximal valve was excised with direct
vision whenever possible. The subsequent valvuloto-
my was performed with either a Mills (V. Mueller,
Irvine, Calif) valvulotome introduced through side
branches or with a “cutter”-type valvulotome intro-
duced from the distal saphenous vein with pulsatile
arterial perfusion of the vein graft. Standard anasto-
motic techniques were used, and completion arteri-
ography or color-flow ultrasound scanning was per-
formed to verify the patency of the bypass graft.
All the patients underwent clinical evaluation in
the immediate postoperative period (30 days) with
duplex color-flow ultrasound scanning. The patients
were followed at 1-month, 3-month, 6-month, and
12-month intervals with color-flow duplex ultra-
sound scanning. Bypass graft occlusion was con-
firmed with duplex scan or arteriographic evalua-
tion. Charge data were obtained from the inpatient
accounting databases of each hospital. The total hos-
pital charges included all services (eg, laboratory ser-
vices, operating room, postoperative care) rendered
during hospitalization. Statistical analysis was per-
formed with the actuarial life-table method to deter-
mine patency over time and with the log-rank test of
significance. Because this study was retrospective in
nature, all statistical analyses must be guarded.
RESULTS
One hundred fifty-six EISB procedures were per-
formed: 41 femoropopliteal and 115 femorocrural.
Ninety-nine of those procedures (63%) were per-
formed through two incisions, 37 of the procedures
(24%) required a third incision, and 20 (13%)
required four or more incisions to ligate large (>5
mm diameter) side branches or residual AVF. In the
156 EISB operations, we performed endovascular
occlusion of 254 (average, 5.2 per case) side branch-
es for femorodistal popliteal bypass grafts and 966
(average, 8.4 per case) side branches for femoro-
crural bypass grafts. Completion arteriographic
results identified residual AVFs in 26 operations
(17%). Small (<2 mm) AVFs were ignored, but an
AVF that immediately filled the deep venous system
or an AVF in which contrast flowed rapidly past an
occlusion coil was ligated through separate small
incisions. The residual AVFs were most often a result
of nonvisualized side branches at the time of opera-
tion and not a failure of side branch embolization.
During the follow-up period, seven AVFs were iden-
tified (5 EISB, 2 CISB) and these were surgically li-
gated (n = 5) or embolized (n = 2).
The mean operative time for the EISB group (235
minutes; range, 105 to 348 minutes) was similar to
that of the CISB group (215 minutes; range, 95 to
355 minutes). During the surgeon’s “learning curve,”
the EISB took longer (mean operative time, 246 min-
utes), but, after the initial six cases, the operative time
decreased (mean operative time, 205 minutes).
An analysis of the postoperative outcomes
between the groups revealed a similar incidence of
perioperative myocardial events. There was one
death in each group, and there were three myocar-
dial infarctions in the CISB group and four in the
EISB group as documented with electrocardiogram
and isoenzyme changes. One of the myocardial
infarctions in the EISB group was believed to be the
result of the excessive intraoperative volume (5.4 L)
that was necessary for angioscopy.
Wound complications after EISB occurred in 4% of
the patients (6 of 156). These were skin edge sloughs
over the femoral or distal incisions in three patients
and seromas in three patients. After CISB, 23% of the
patients (27 of 117) had wound complications, includ-
ing full thickness (n = 5) and superficial (n = 8) skin
sloughs along the thigh or calf incisions, hematomas
(n = 9), and seromas (n = 5; P = .003). Nine patients
who underwent CISB required hospital readmission
for wound care. After operation, the mean hospital
length of stay (LOS) for the patients who underwent
EISB was 3.2 days (± 3.19) versus 6.5 days (± 4.83)
for the patients who underwent CISB (P = .001).
During the follow-up period, all the available
patients underwent color-flow duplex ultrasound
scanning to verify graft patency. Eleven patients (3
EISB, 8 CISB) were lost to follow-up examination.
The primary patency rate at 39 months of the follow-
up period (mean, 16.6 months; range, 1 to 40
months) with life-table analysis was 78.2% (± 5%) for
the CISB group versus 70.5% (± 5%) for the EISB
group. The rates were not statistically different (P =
.156; Table II; Fig 1). Twenty-four of the EISB
grafts (15.3%) occluded within 12 months of opera-
tion. These early graft failures were attributed to inti-
mal trauma from the endovascular instruments in 19
grafts in which smaller veins (< 3.0 mm in diameter)
were used. There were 10 CISB early graft failures
(8.5%), but only six grafts used smaller veins. Overall,
31 grafts in the EISB group and 28 grafts in the
CISB group were less than 3.0 mm in diameter. Of
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these EISB grafts, 68% (21 of 31) failed, as opposed
to only 39% (11 of 28) of the CISB grafts, which was
not statistically different. Careful color-flow ultra-
sound scan graft surveillance results rendered sec-
ondary patency rates that were similar between the
CISB group (84.1% ± 4%) and the EISB group
Fig 2. Secondary patency rates for conventional (CISB)
and endovascular (EISB) in situ bypass grafting procedures.
Table II. Cumulative primary patency rates for conventional and endovascular-assisted in situ bypass grafts
No. of grafts No. of grafts No. of grafts Interval patency Cumulative patency
Interval at risk failed withdrawn rate (%) rate (%) SE
0 to 3 months
CISB 117 4 6 96.5 100.0 1.7
EISB 156 7 8 95.4 100.0 1.7
3 to 6 months
CISB 102 2 10 98.0 96.5 2.1
EISB 132 6 8 97.7 95.4 2.0
6 to 9 months
CISB 86 2 19 97.6 94.6 2.6
EISB 108 6 23 97.8 93.2 2.8
9 to 12 months
CISB 70 2 10 97.1 92.4 3.1
EISB 81 5 21 97.3 88.1 3.5
12 to 15 months
CISB 57 1 10 98.2 89.7 3.5
EISB 61 1 9 98.4 82.6 3.8
15 to 18 months
CISB 47 3 8 93.6 88.1 3.5
EISB 51 3 8 94.1 81.2 3.8
18 to 21 months
CISB 36 1 9 97.2 82.5 4.5
EISB 41 2 7 95.0 76.5 4.4
21 to 24 months
CISB 28 0 5 100.0 80.2 5.0
EISB 33 1 5 96.7 72.7 5.0
24 to 27 months
CISB 23 0 4 100.0 80.2 5.0
EISB 25 0 8 100.0 70.5 5.3
27 to 30 months
CISB 19 1 4 93.4 79.2 5.0
EISB 19 0 4 100.0 70.5 5.3
30 to 33 months
CISB 14 0 5 100.0 78.2 5.0
EISB 13 0 9 100.0 70.5 5.3
33 to 36 months
CISB 9 0 5 100.0 78.2 6.2
EISB 7 0 3 100.0 70.5 5.3
36 to 39 months
CISB 5 0 2 100.0 78.2 6.2
EISB 4 0 3 100.0 70.5 5.3
CISB, Conventional in situ bypass grafting; EISB, endovascular-assisted in situ bypass grafting.
Fig 1. Primary patency rates for conventional (CISB) and
endovascular (EISB) in situ bypass grafting procedures. 
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(82.9% ± 5%; P = .26; Table III; Fig 2). Close follow-
up examination of all the patients and aggressive revi-
sionary efforts resulted in an 85.8% limb salvage rate
for the patients who underwent CISB and an 88.4%
rate for the patients who underwent EISB. This was
not statistically different (P = .12).
DISCUSSION
Since the first saphenous vein in situ bypass graft-
ing procedure performed by Charles Robb in 1959
and subsequently reported by Karl Viktor Hall in
1962,2 surgeons have attempted to make the in situ
bypass grafting operation less invasive, while simplify-
ing the two principle technical components of the
operation, rendering the saphenous vein values
incompetent and occluding the venous side branches.
In 1992, Rosenthal et al3 reported on an endovas-
cular technique that used an electronically guided,
steerable nitinol catheter with fluoroscopic surveillance
with stainless steel coils to occlude venous side branch-
es during in situ saphenous vein bypass grafting. Since
this initial report, the instrumentation and technique
of operation have undergone several generations of
change, and today, EISB is performed with an angio-
scopically guided Side Branch Occlusion system and a
retrograde Fogarty irrigating valvulotome. With this
system, valvulotomy and side branch occlusion can be
easily and safely performed in a “one-pass” fashion
down the saphenous vein. The limiting factor of EISB
is the requisite size and quality of the saphenous vein.
In veins that are less than 3 mm in diameter, the
endovascular technique is not appropriate because the
Table III. Cumulative secondary patency rates for conventional and endovascular-assisted in situ bypass grafts
No. of grafts No. of grafts No. of grafts Interval patency Cumulative patency
Interval at risk failed withdrawn rate (%) rate (%) SE
0 to 3 months
CISB 117 2 6 98.3 100.0 0
EISB 156 5 8 96.7 100.0 0
3 to 6 months
CISB 103 2 11 98.1 98.3 1.2
EISB 133 2 21 98.5 96.7 1.5
6 to 9 months
CISB 87 2 19 97.7 96.4 1.8
EISB 109 1 23 98.1 95.3 1.8
9 to 12 months
CISB 70 1 11 98.6 94.1 2.3
EISB 84 2 24 97.6 94.4 2.0
12 to 15 months
CISB 58 0 10 100.0 92.3 2.7
EISB 64 1 13 98.4 92.1 2.7
15 to 18 months
CISB 49 3 8 93.8 92.3 2.7
EISB 52 2 9 96.1 90.1 2.8
18 to 21 months
CISB 37 0 10 100.0 87.1 4.1
EISB 42 2 7 95.2 87.2 3.7
21 to 24 months
CISB 30 0 5 100.0 87.1 4.1
EISB 33 0 6 100.0 82.9 4.5
24 to 27 months
CISB 25 1 4 92.1 84.1 5.0
EISB 26 0 8 82.9 4.5
27 to 30 months
CISB 20 0 5 100.0 84.1 5.0
EISB 20 0 4 100.0 82.9 4.5
30 to 33 months
CISB 15 0 6 100.0 84.1 5.0
EISB 14 0 9 100.0 82.9 4.5
33 to 36 months
CISB 9 0 2 100.0 84.1 5.0
EISB 8 0 3 100.0 82.9 4.5
36 to 39 months
CISB 5 0 3 100.0 84.1 5.0
EISB 8 0 3 100.0 82.9 4.5
CISB, Conventional in situ bypass grafting; EISB, endovascular-assisted in situ bypass grafting.
Side Branch Occlusion system diameter (2.6 mm) may
cause intimal trauma that could result in early graft fail-
ure. Although all the patients underwent preoperative
color-flow ultrasound scanning, this critical outside
vein diameter was determined in the operating room
after gentle distention with heparinized saline solution.
This may explain why 15% of the EISB grafts (24 of
156) failed within 12 months and in 19 grafts that
were less than 3 mm in diameter. Overall, 68% of the
EISB grafts (21 of 31) that were performed with these
smaller veins failed. Comparatively, 39% of the CISB
grafts (11 of 28) that were performed with veins less
than 3 mm in diameter failed. Most of these EISB
graft failures occurred early in our experience when we
were more aggressive with smaller veins and were try-
ing to do all the bypass grafting procedures with the
endovascular technique. A concern with this retro-
spective study is bias of patient selection because
patients with smaller saphenous veins were excluded
late in the study from the endovascular group. It was
of interest to note, however, that 31 of the EISB pro-
cedures (20%) were performed with veins that were
less than 3 mm in diameter and that 28 in the CISB
group (24%) were performed on these veins, which
indicates that patient selection did not inadvertently
bias the results. Nevertheless, at 39 months of the fol-
low-up period, the primary patency rates (EISB, 70.5%;
CISB, 78.2%), secondary patency rates (EISB, 
82.9%; CISB, 84.1%), and limb salvage rates (EISB, 
88.4%; CISB, 85.8%) were statistically similar and
comparable with recent reports from the Brigham and
Women’s Hospital4 (72% primary, 80% secondary)
and the Albany Medical College5 (77% primary, 86%
secondary) for the same length of follow-up period.
Significant wound complications after femoro-
popliteal-tibial bypass grafting with saphenous vein
are common and have been reported in up to one
third of the cases.6-8 These are often the results of
ischemia of the skin flap caused by dissection of the
saphenous vein, which may initiate cellulitis, lym-
phangitis, edema, and fat necrosis. Wound complica-
tions after EISB occurred in 4% (6 of 156) versus
23% (27 of 117) of the CISB operations, which was
statistically significant (P = .003). If a wound com-
plication occurred, the patients were discharged on
the basis of the surgeon’s discretion to either an
extended care facility or to home nursing. Whenever
possible, EISB was performed through two inci-
sions, with distal anterior tibial grafts requiring a
third incision for anastomosis. In 57 cases (37%),
however, an additional incision was necessary to li-
gate a residual AVF or a large (> 5 mm in diameter)
side branch. As anticipated, because of the minimal-
ly invasive nature of the operation, the mean hospi-
tal LOS was markedly shortened (3.2 days) in the
patients who underwent EISB versus the patients
who underwent CISB (6.5 days). This was statisti-
cally significant (P = .001).
Indeed, at the 1998 New England Society for
Vascular Surgery meeting, Nelson and Arous9
reported a mean hospital LOS of only 32 hours 
(± 14.3 hours) in 12 patients who underwent EISB.
With the obviation of the need for an incision, the
length of the leg, wound complications and hospital
LOS were greatly reduced in the EISB group.
In this era of healthcare cost containment, a
concern that must be addressed is the cost efficacy
of the endovascular procedure. Hospital administra-
tive and accounting data retrieval systems usually
record charges rather than the actual costs for hos-
pital stay, which may be a limitation in this study.
Charges, as billed to third-party payers, often
exceed the actual costs. These costs can be readily
obtained with traditional tools of cost accounting.10
These cost-to-charge ratios can be used to estimate
the underlying costs of a procedure by multiplying
the charges for that procedure with the appropriate
cost-to-charge ratio.11 Unfortunately, cost-to-charge
data were not available in this multicenter, retro-
spective study. The hospital charges, however, were
evaluated for the CISB and EISB groups, one
against the other within the same hospital, not one
hospital against another.
It is of interest to note the 1997 Healthcare
Finance Administration data on diagnosis-related
group payment for 17,144 patients admitted with a
diagnosis of atherosclerosis of the lower extremity
with rest pain, ulceration, and gangrene (ICD.9
codes 440.22-24) who underwent in situ vein
bypass grafting (CPT codes 35583, 35585). These
data showed a mean hospital LOS of 7.0 days and a
mean loss (mean charges of $21,544 minus mean
reimbursement of $10,706) of almost $10,784 per
patient, or $18,360,000 annually.12 In this study,
the mean hospital charges for patients who under-
went CISB were $25,349 per patient, which, after
subtracting for a mean reimbursement of $10,760,
yielded a loss of $14,589 per patient. In the EISB
group, the mean hospital charges were $18,096,
which, after reimbursement ($10,760), reduced the
loss to the hospital by almost half ($7336). If hospi-
tal LOS continues to decrease for patients who
undergo EISB and the incidence of wound compli-
cations remains low, it appears that this technique
will benefit the patient by virtue of being a less inva-
sive operation and that we will narrow the gap
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towards profitability for the hospital while justifying
the additional expense of the endovascular instru-
mentation ($2000) as well.13
CONCLUSION
The CISB and EISB midterm primary and sec-
ondary patency and limb salvage rates were statisti-
cally similar. In smaller veins (< 3.0 mm in diame-
ter), however, the endovascular procedure is not
appropriate because overly aggressive instrumenta-
tion may cause intimal trauma with resultant early
graft failure. With the avoidance of a long leg inci-
sion in the EISB group, wound complications and
hospital LOS were significantly reduced, which low-
ered hospital charges and justified any additional
cost of the endovascular instruments. This study
faces the limitations of all retrospective studies, and
conclusions should be guarded. A prospective, mul-
ticenter study is now enrolling patients, and, as the
second generation endovascular instrumentation 
is improved with new, “slippery,” hydrophilic-like
catheter coatings and as refinements of component
parts continues, the limitations and the ultimate role
of the EISB will be resolved. Nevertheless, when in
situ bypass grafting is indicated, the EISB is current-
ly a safe, minimally invasive, and cost-effective oper-
ation in appropriate patients.
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Dr Julie Ann Freischlag (Los Angeles, Calif). It is my
pleasure to discuss this paper comparing endovascular ver-
sus conventional in situ vein bypass grafting techniques in a
large group of patients (n = 237) over a period of 7 years
from 11 different medical centers. The endoscopic tech-
nique involves a rather complex system using a proximally
inserted Side Branch Occlusion system and a distally insert-
ed irrigating valvulotome. The conventional method used a
full-length incision to expose the entire greater saphenous
vein and the valves were cut from the distal end with pul-
satile arterial perfusion of the graft. I have several questions.
First, how did you recruit your patients? How were the
patients enrolled in this study? You state it is a concurrent,
retrospective multicenter study. What does that mean? Why
did it take 11 centers 7 years to find these patients? And
were they consecutive? And why was it not prospective? By
excluding the small veins, less than 3 mm, did you set up a
bias for the conventional technique to fare more poorly?
Second, regarding your endoscopic device, is it easy to
use? How much volume on an average is infused into a
patient to perform the procedure? And why did you use arte-
riography in these patients after the procedure and not just
duplex scanning? And can you tell us what anatomic prob-
lem caused the failures in the 24 grafts that occluded during
the first 12 months? Were they attributed to vein damage?
Third, at the University of California–Los Angeles, the
length of stay for patients who undergo distal bypass graft-
ing with the conventional greater saphenous vein tech-
niques, and more often than not the splicing of veins
together from many different sites, is 3 days, on average,
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despite our multitude of incisions. The cost savings in
your endovascular group was caused by decreased length
of stay, as you did state the device adds $2000 to the cost
of hospitalization. If your length of stay goes down in your
conventional group, how can you justify the cost of this
device? Should the manufacturer lower the cost of the
device?
Sadly, your cost savings reported by this group was
reported as a decrease in loss to the hospital: $14,589 per
patient in the conventional group and $7336 per patient in
the endoscopic group. I sure hope that Dr Zarins is right and
that the reimbursement will only get better over the next 10
years because I feel our cost cannot get much lower.
Thank you for the privilege of discussing this paper.
Dr David Rosenthal. We used the term concurrent,
retrospective study to indicate that patients underwent
operation by the same surgeons with either the endovas-
cular or conventional procedure and that the open or con-
ventional operations served as historic controls.
Three of the investigators—myself, John Martin, and
John Piano—began using the endovascular in situ bypass
grafting technique in 1995. The Side Branch Occlusion
system and valvulotome were approved by the Food and
Drug Administration in March 1997, and, as surgeons
were being trained in the endovascular technique, patients
were enrolled in this study. Hence, the 11 centers.
Did we bias the results for the conventional patients
by excluding the smaller veins from the endovascular
group? I think not, and I say this because 31, or roughly
20%, of our endovascular in situ bypass grafting proce-
dures were performed with veins less than 3 mm in diam-
eter, which was similar to the control open group and
indicates that many of the conventional operations were
done with larger veins as well.
This study was not prospective, because 5 years ago
when we started using this technique, we honestly did not
know where all this was going. There is currently a multi-
center, prospective study underway, and we hope to bring
this information before this Society in the years ahead.
Your next question had to do with how easy it is to use
the endoscopic technique. This is obviously difficult to
answer, but I would compare the technique to where
laparoscopic cholecystectomy was 10 years ago. We all
remember the 2-hour laparoscopic cholecystectomy pro-
cedures, which now take 25 minutes. I believe we are at
the beginning stages of this technique, and there is a def-
inite learning curve, which we think is about six cases. The
surgeons who seem to pick this up the most rapidly are
those with previous angioscopic expertise and surgeons
with laparoscopic skills.
How much volume is infused on average? John
Martin, one of my co-investigators, did a study analyzing
the learning curve of surgeons from their first 116 opera-
tions. Early in the surgeon’s experience, 2 to 3 L of fluid
was frequently used, but as they gained more sophistica-
tion, the irrigation volume decreased on average to
approximately 1500 mL. Pragmatically, what I do is to
instruct the anesthesiologist to keep the patient “bone
dry.” When we use more than 1500 mL of irrigation, the
patient is given a gentle diuretic. For example, after 20 mg
of Furosemide, what we irrigated with is in the Foley bag
a half hour later.
Arteriography was used to confirm occlusion of
venous side branches, patency of the bypass grafts, and coil
position. Brad Johnson, one of our other investigators
from the University of South Florida who works with
Dennis Bandyk, is hopefully developing ultrasound scan
criteria for the endovascular procedure to document side
branch occlusion.
The graft failures you asked about in our endovascular
group within the first year, as I mentioned, predominate-
ly were in “smaller” veins. Of these 24 graft failures, 19
were in veins that were less than 3 mm in diameter, which
was unacceptable. Obviously, if the diameter of the side
branch occlusion catheter is 2.6 mm and we are in a 3 mm
or smaller vein, “it ain’t going to happen.”
Your comment about the length of stay at the
University of California–Los Angeles of 3 days I think is
reasonable, but I would encourage everyone to look up
their data on hospital length of stay because one serious
wound problem and a 10-day stay really skews the data. I
think it is important to remember that the cost savings in
the endovascular group was not only the result of the
decreased hospital length of stay but also of a six-fold
decrease in the incidence of wound complications. I can
assure you that as you read the literature, the wound com-
plication rate that comes up again and again after saphe-
nous vein harvest approaches 25%. We are not operating
on 25-year-old Marines; these are 75-year-old diabetic
patients with compromised tissues, and if you do not think
wound complications are expensive, everyone should put
a pencil to it. In Atlanta, at my hospital, a bed per day is
$350, 3 gm of vancomycin hydrochloride is $1200, and
some Kerlex gauze, tape, and saline solution is $150. So,
in one day, by avoiding a wound complication while
reducing the length of stay, we have essentially paid for the
cost of the instrumentation.
One final thought, which is difficult to put on a cal-
culator, is patient satisfaction. As we all know, if you ask
any patient, who has undergone saphenous vein harvest-
ing for coronary bypass grafting, reversed vein grafting, or
open in situ grafting, 10 months after the operation what
hurts, they will tell you the same thing: what plagues them
is the limb edema and the neuralgias from the incisions. I
would hope that if this endovascular technique proves as
durable as our other operations, these problems can be
obviated for our patients.
Dr Robert B. Rutherford (Silverthorne, Colo). You
made the point about the importance of wound complica-
tions in this comparison, especially when you get to length
of stay and cost. In this study, you have combined two
techniques, that of valvulotome and that of the side
branch occluder. And you have set up a pretty tough straw
man in using the totally open approach to exposure for
valvulotomy and branch occlusion, rather than a more lim-
ited approach, which many use for going after the signifi-
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cant arteriovenous fistulas with a Doppler scan after closed
valvutomy. I would like to see a comparison of two groups
in which the same valvulotome was used but the side
branch occluder was compared with the more limited inci-
sion approach to residual arteriovenous fistulas. Do you
have any thoughts on that or any data on that aspect of the
comparison?
Dr Rosenthal. I do not have any data on that, but it is a
fair question. The so-called “picket fence” technique is cer-
tainly an appropriate operation that yields good results.
Unfortunately, I do not have any data with this technique
for you. It is interesting that I used this technique with the
angioscope before we started the side branch occlusion
technique. As everyone who has used this technique knows,
one drawback is when you are operating in those large
thighs and you are looking for the arteriovenous fistulas
with a Doppler scan, or when you have tried to mark them
on the skin from the angioscope transillumination, or when
you have several arteriovenous fistulas in sequence, the small
2-cm incisions quickly become a major cut.
When the “picket fence” incisions work well, it is great
and probably should be compared with the side branch
occlusion technique. Right now, in the multicenter
prospective trial, most of the open in situ grafting proce-
dures are still done with a continuous incision, but that is
something worth looking into. Fair comment.
Dr Frank T. Padberg, Jr (East Orange, NJ). Like you,
we have tried to reduce the length of the incision with
endoscopic techniques. Your technique is attractive
because it does offer reduced wound complications for an
in situ bypass graft. However, your technique does not
offer the option of converting to a transposed or a
reversed vein. I would wonder, have you any thoughts
about the technical means that this technique could be
adapted to use for that purpose?
I am concerned, as was Dr Freischlag, about the 3 mm
vein size. How is this measured? If you do vein mapping
beforehand, you could have excluded veins that were
smaller than 3 mm from both arms of your study, giving
you a comparable group between the two. Could you
comment on that, please?
Dr Rosenthal. All the patients in the series underwent
color-flow ultrasound scanning and vein mapping in the
supine position before the operation. The size again was
evaluated in the operating room at the time of dilation of
the vein with heparin saline solution insufflation through
the distal vein. This is really the true measurement of the
vein diameter and at this point the judgment is made to
use the endovascular technique or not. Again, this is a ret-
rospective study. Your statement is correct, and in the
prospective trial, we should exclude veins less than 3 mm
in both groups.
Your first question had to do with converting the in
situ bypass grafting to a transposed or reversed vein graft-
ing, which could only be done if you opened the leg and
harvested the vein.
Dr Padberg. Do you have any plans to adapt this so
that we can perform either transposed or reversed grafting?
Dr Rosenthal. No, this technique is for in situ bypass
grafting only. If you are interested in a minimally invasive
technique to harvest saphenous vein, the work by Luis
Sanchez at Montefiore and Will Jordan at the University
of Alabama, amongst others, with the laparoscopic systems
and side branch clipping is another alternative.
